# OnCo record phoenix (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/phoenix/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "phoenix", "NCT03740893" ;
  schema:name "PHOENIX DDR/Anti-PD-L1"@en ;
  schema:alternateName "PHOENIX"@en ;
  schema:description "PHOENIX, a UK trial from the Institute of Cancer Research, gives women whose triple-negative breast cancer has not responded fully to pre-operative chemotherapy a short course of a DNA-repair drug (olaparib or ceralasertib) or immunotherapy (durvalumab) before surgery, and measures what it does to the tumour, to find which patients could benefit from these drugs after surgery."@en ;
  schema:url <https://onco.cc/trials/phoenix/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03740893> ;
  onco:status "recruiting" ;
  onco:phase "2" ;
  onco:cancers <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/tnbc-early/> ;
  onco:technologies <https://onco.cc/technologies/parp-inhibitor/>, <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/atr/>, <https://onco.cc/targets/parp/>, <https://onco.cc/targets/pdl1/> ;
  onco:drugs <https://onco.cc/drugs/olaparib/>, <https://onco.cc/drugs/ceralasertib/>, <https://onco.cc/drugs/durvalumab/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/> ;
  onco:institutions <https://onco.cc/institutions/cruk/> ;
  onco:terms <https://onco.cc/terms/rcb/>, <https://onco.cc/terms/tils/>, <https://onco.cc/terms/ctdna/>, <https://onco.cc/terms/tnbc-residual-disease-decision/> ;
  onco:trials <https://onco.cc/trials/keynote-522/>, <https://onco.cc/trials/partner/> .